Q-omics provides the consensus-scored C17orf77 profile across patient tissues and cancer cell-line models. C17orf77 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C17orf77 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, C17orf77 RNA expression shows 6,774 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UVM, COAD, and LAML as cancer lineages where C17orf77 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf77 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf77 survival associations across molecular data types. C17orf77 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf77 RNA expression–survival associations across cancer types. High C17orf77 expression shows unfavorable associations in UVM, LUAD, DLBC, LUSC and CESC, but favorable associations in READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C17orf77 RNA expression.
This table summarizes C17orf77 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C17orf77. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf77 shows lower tumor expression in BRCA and LIHC and higher tumor expression in COAD, READ and LIHC. The COAD box plot shows higher C17orf77 RNA expression in tumor versus normal tissue (log2 FC = +1.366, t-test p < 0.001).
This table shows molecular features associated with C17orf77 in patient tissues and cancer cell lines. In patient samples, C17orf77 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf77 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
